×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📊
Dashboards
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Dashboards
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
←
Home
/
Wiki
/
Company: PD ATP13A2/PARK9 Lysosomal Therapy Companies
company
684 words
KG: PD
Contents
PD ATP13A2/PARK9 Lysosomal Therapy Companies
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (28)
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
Arginine Methylation Enhancement Therapy
Score: 0.65
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
HCN1-Mediated Resonance Frequency Stabilization Therapy
Score: 0.65
TFEB-PGC1α Mitochondrial-Lysosomal Decoupling
Score: 0.62
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
Lysosomal Membrane Repair Enhancement
Score: 0.54
← Prev
pg 2/2
Related Analyses (17)
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Show 12 more
Related Experiments (3)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Synaptic Mitochondrial Resilience Enhancement for Parkinson'
validation · proposed · Score: 0.40
Knowledge Graph (12 edges)
PD
causes
NEURODEGENERATION
PD
causes
DOPAMINERGIC_NEURONS
PD
causes
neurodegeneration
NEUROTROPHINS
treats
PD
AGE
associated_with
PD
SNCA
causes
PD
LRRK2
causes
PD
GBA1
causes
PD
PRKN
causes
PD
PINK1
causes
PD
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)